骨溶解
兰克尔
破骨细胞
癌症研究
骨转移
肿瘤微环境
转化生长因子
骨吸收
转移
乳腺肿瘤
癌症
肿瘤进展
化学
乳腺癌
医学
激活剂(遗传学)
受体
内科学
肿瘤细胞
外科
作者
Mitsuru Futakuchi,Kalyan C. Nannuru,Michelle L. Varney,Anguraj Sadanandam,Kimihisa Nakao,Kiyofumi Asai,Tomoyuki Shirai,Shinya Sato,Rakesh Kumar Singh
标识
DOI:10.1111/j.1349-7006.2008.01012.x
摘要
Understanding the cellular and molecular changes in the bone microenvironment is important for developing novel therapeutics to control breast cancer bone metastasis. Although the underlying mechanism(s) of bone metastasis has been the focus of intense investigation, relatively little is known about complex molecular interactions between malignant cells and bone stroma. Using a murine syngeneic model that mimics osteolytic changes associated with human breast cancer, we examined the role of tumor-bone interaction in tumor-induced osteolysis and malignant growth in the bone microenvironment. We identified transforming growth factor-beta receptor 1 (TGF-betaRI) as a commonly upregulated gene at the tumor-bone (TB) interface. Moreover, TGF-betaRI expression and activation, analyzed by nuclear localization of phospho-Smad2, was higher in tumor cells and osteoclasts at the TB interface as compared to the tumor-alone area. Furthermore, attenuation of TGF-beta activity by neutralizing antibody to TGF-beta or TGF-betaRI kinase inhibitor reduced mammary tumor-induced osteolysis, TGF-betaRI expression and its activation. In addition, we demonstrate a potential role of TGF-beta as an important modifier of receptor activator of NF-kappaB ligand (RANKL)-dependent osteoclast activation and osteolysis. Together, these studies demonstrate that inhibition of TGF-betaRI signaling at the TB interface will be a therapeutic target in the treatment of breast cancer-induced osteolysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI